199172-01-5

Basic information

• Product Name: 6-BROMO-3-ETHYL-1H-INDAZOLE
• Synonyms: 6-BROMO-3-ETHYL-1H-INDAZOLE;1H-Indazole, 6-broMo-3-ethyl-
• CAS NO: 199172-01-5
• Molecular Formula: C₉H₉BrN₂
• Molecular Weight: 225.0852
• Mol File: 199172-01-5.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 350.923 °C at 760 mmHg
• Flash Point: 166.033 °C
• Appearance: /
• Density: 1.562 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.671
• PKA: 13.17±0.40(Predicted)
• CAS DataBase Reference: 6-BROMO-3-ETHYL-1H-INDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BROMO-3-ETHYL-1H-INDAZOLE(199172-01-5)
• EPA Substance Registry System: 6-BROMO-3-ETHYL-1H-INDAZOLE(199172-01-5)

Safety Data

• Hazardous Substances Data: 199172-01-5(Hazardous Substances Data)

Usage

General Description

6-Bromo-3-ethyl-1H-indazole is a chemical compound with the molecular formula C9H9BrN2. It belongs to the class of indazoles, which are heterocyclic aromatic compounds with a five-membered ring containing two nitrogen atoms. 6-BROMO-3-ETHYL-1H-INDAZOLE is a derivative of indazole, a bicyclic heterocycle which has been studied for its potential pharmacological properties. 6-Bromo-3-ethyl-1H-indazole is used in research and development, particularly in the synthesis of pharmaceuticals and agrochemicals. It may also have potential applications in the field of medicinal chemistry, where its structure and properties can be further explored for the development of new drugs and biologically active compounds.

InChI:InChI=1/C9H9BrN2/c1-2-8-7-4-3-6(10)5-9(7)12-11-8/h3-5H,2H2,1H3,(H,11,12)

Upstream product

• 3355-21-3 5-Bromo-2-propyl-phenylamine 
• 67-56-1 methanol 
• 13826-83-0 ammonium tetrafluroborate 
• 60-29-7 diethyl ether 
• 1049651-71-9 1-(6-bromo-3-ethyl-1H-indazol-1-yl)ethanone 
• 1214900-59-0 1-(4-bromo-2-fluorophenyl)propan-1-ol 
• 259750-61-3 1-(4-bromo-2-fluorophenyl)propan-1-one 
• 57848-46-1 4-bromo-2-fluorobenzaldehyde 

Downstream Products

• 1300582-48-2 tert-butyl 6-bromo-3-ethyl-1H-indazole-1-carboxylate 
• 1300585-17-4 2-(1-(4-amino-3-(3-ethyl-1H-indazol-6-yl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)ethyl)-3-(3-fluorophenyl)-4H-chromen-4-one 
• 1049651-73-1 1-(4-methoxybenzyl)-6-bromo-3-ethyl-1H-indazole 

Relevant articles and documents

RING-FUSED COMPOUND

The present invention relates to a compound that has URAT1 inhibitory action, and a URAT1 inhibitor, a blood uric acid level-reducing agent and a pharmaceutical composition comprising the compound. More specifically, the present invention relates to a compound represented by Formula (I) below. [in the formula, R1 is -Q1-A1 and the like; ---- is a double bond or a single bond; when ---- is a double bond, W1 is a nitrogen atom or a group represented by the general formula: =C(Ra)-, and W2 is a nitrogen atom or a group represented by the general formula: =C(Rb) -; when ---- is a single bond, W1 is a group represented by the general formula: -C(Raa)(Rab)- or a group represented by the general formula: -(C=O) -, and W2 is a group represented by the general formula: C(Rba)(Rbb)-, a group represented by the general formula: - (C=O) - or a group represented by the general formula: -N(Rbc)-; W3, W4 and W5 are each independently a nitrogen atom or a methine group and the like that may have a substituent; X is a single bond, an oxygen atom and the like; Y is a single bond or (CRYiRYi')n; and Z is a hydroxyl group or COOR2 and the like.

6' SUBSTITUTED COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY

The present disclosure provides compounds having affinity for the 5-HT6 receptor which are of the formula (I): wherein R1—R4 A, B, D, E, and G are as defined herein. The disclosure also relates to methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.

THERAPEUTICALLY ACTIVE COMPOUNDS BASED ON INDAZOLE BIOISOSTERE REPLACEMENT OF CATECHOL IN PDE4 INHIBITORS

Therapeutically active compositions of matter are described which are useful for treating or preventing diseases and conditions comprising inflammatory diseases including joint inflammation, Crohn's disease, and inflammatory bowel disease; respiratory dis